Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kyorin: Ethical Drug Sales Down 5.7% to \51.5 Bil.
June 7, 2004
- GVP, GQP GLs to Be Announced in July
June 7, 2004
- Mochida: Profits Down Sharply due to Increase in Investment Costs
June 7, 2004
- REGULATORY NEWS IN BRIEF
June 7, 2004
- Zeria: Sales Down 1.2% to \54.3 Bil.
June 7, 2004
- PRESS SEMINR
June 7, 2004
- Nikken Chemicals: Drug Division Sales Down 3.8% to \41.2 Bil.
June 7, 2004
- OTC NEWS IN BRIEF
June 7, 2004
- Nippon Shinyaku: Drug Division Sales Down 4.4% to \42.4 Bil.
June 7, 2004
- Annual Business Results
June 7, 2004
- Fuso: 1st Increase in Ordinary Profits in 3 Years
June 7, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 7, 2004
- Teikoku Hormone: Drug Division Sales Slip 4.1% to \18.6 Bil.
June 7, 2004
- Annual Business Results
June 7, 2004
- Sumitomo Pharmaceuticals: Sales Fall 1% to \136.9 Bil.
June 7, 2004
- Semiannual Business Results
June 7, 2004
- JPMA to Help Industry Contribute to Global Healthcare: Dr Aoki
June 7, 2004
- Towa Yakuhin: Sales of \23.1 Bil. Make It No.1 GE Maker
June 7, 2004
- Takara Bio Reports Antithrombotic Action of Fucoidan Oligosaccharides
June 7, 2004
- Annual Business Results
June 7, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…